{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:03Z","timestamp":1786977423975,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Weekly or daily cisplatin and 5\u2010fluorouracil (5\u2010FU)\u2010based chemoradiation was evaluated for patients with locally advanced squamous cell carcinoma (SCC) of the anal canal treated at a single institution over a 20\u2010year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A retrospective, single\u2010institution analysis was conducted of patients receiving concurrent 5\u2010FU\/cisplatin and radiotherapy for locally advanced SCC from 1989 to 2009. Endpoints included clinical complete response rate, local recurrence rate, colostomy\u2010free survival, disease\u2010free survival (DFS), overall survival, and treatment\u2010related toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 197 patients were evaluable. The majority had American Joint Committee on Cancer stage II (41%) or stage III (46%) disease; most were T2 (44%) or T3 (27%); bulky nodal disease (N2\u2010N3) was noted in 24% of patients. Patients received weekly (20 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) or daily (4 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) cisplatin during radiotherapy. Median radiation dose was 55 Gy. Clinical complete response was observed in 185 patients (94%). After a median follow\u2010up of 8.6 years, local recurrence rate was 11%. Sixteen patients (8%) developed distant metastases. The 5\u2010year DFS was 81%, the 5\u2010year overall survival was 86%, and the 5\u2010year colostomy\u2010free survival was 88%. By univariate analysis, N\u2010stage was a poor prognostic indicator for 5\u2010year DFS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02, 95% confidence interval\u2009=\u20091.17\u20102.01) and distant metastases (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.046, 95% confidence interval\u2009=\u20091.09\u20102.13). Increased T\u2010stage correlated with the necessity for salvage surgery (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The combination of weekly\/daily cisplatin and 5\u2010FU\u2013based chemotherapy with concurrent radiotherapy is an effective regimen, and our long\u2010term results indicate that cisplatin is an alternative to mitomycin C and may be considered for the treatment of locally advanced SCC of the anal canal. Cancer 2013;119:3769\u20133775. \u00a9 2013 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.28296","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T10:44:14Z","timestamp":1376995454000},"page":"3769-3775","source":"Crossref","is-referenced-by-count":30,"title":["Long\u2010term results of weekly\/daily cisplatin\u2010based chemoradiation for locally advanced squamous cell carcinoma of the anal canal"],"prefix":"10.1002","volume":"119","author":[{"given":"Cathy","family":"Eng","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Chang","sequence":"additional","affiliation":[{"name":"Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Nancy","family":"You","sequence":"additional","affiliation":[{"name":"Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[{"name":"Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[{"name":"Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Delclos","sequence":"additional","affiliation":[{"name":"Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Rodriguez\u2010Bigas","sequence":"additional","affiliation":[{"name":"Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Skibber","sequence":"additional","affiliation":[{"name":"Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Ohinata","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Gould","sequence":"additional","affiliation":[{"name":"Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.2339"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11161"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_9_1","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_7_11_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations)","author":"Howlader N","year":"2012"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31817aebfe"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1223841"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4030","article-title":"Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5\u2010fluorouracil (5\u2010FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV\u2010positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results [Abstract]","volume":"30","author":"Garg M","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28296","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:50:33Z","timestamp":1760287833000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":13,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/cncr.28296"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28296","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}